An HSV-2-based oncolytic virus deleted in the PK domain of the ICP10 gene is a potent inducer of apoptotic death in tumor cells
Authors:
Open Access
- 31 May 2007
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 14 (16) , 1218-1225
Abstract
The N-terminus of the ICP10 gene of type 2 herpes simplex virus (HSV-2) encodes a serine/threonine protein kinase (PK) domain that facilitates HSV-2 replication by activating the Ras/MEK/MAPK mitogenic pathway and suppressing apoptosis. We recently demonstrated that deletion of this oncogenic PK domain converts it to a potent oncolytic agent. This mutant, which we have designated FusOn-H2, preferentially replicates in and thus lyses tumor cells in which the Ras signaling pathway is constitutively activated. Here we show that FusOn-H2 exerts strong ability in inducing apoptosis in different lines of human tumor cells and in esophageal tumors growing in mice. The apoptotic effect produced by FusOn-H2 was not restricted to infected cells but extended to uninfected bystander cells, thereby increasing the lethality of the virus. These results add a novel killing mechanism to those previously assigned to FusOn-H2, rendering it an attractive candidate for clinical trials.Keywords
This publication has 29 references indexed in Scilit:
- A Mutant Type 2 Herpes Simplex Virus Deleted for the Protein Kinase Domain of the ICP10 Gene Is a Potent Oncolytic VirusMolecular Therapy, 2006
- Oncolytic herpes simplex virus vectors for cancer virotherapyCancer Gene Therapy, 2002
- The Herpes Simplex Virus Type 2 R1 Protein Kinase (ICP10 PK) Blocks Apoptosis in Hippocampal Neurons, Involving Activation of the MEK/MAPK Survival PathwayJournal of Virology, 2002
- Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1Nature Cell Biology, 2001
- Induction of apoptosis by herpes simplex virus type 1.Journal of General Virology, 1997
- A Novel Multiply-Mutated HSV-1 Strain for the Treatment of Human Brain TumorsHuman Gene Therapy, 1997
- Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma.Proceedings of the National Academy of Sciences, 1995
- The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells.Proceedings of the National Academy of Sciences, 1992
- Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus MutantScience, 1991
- Mapping of Herpes Simplex Virus-1 Neurovirulence to γ 1 34.5, a Gene Nonessential for Growth in CultureScience, 1990